

**REMARKS*****Response to Restriction Requirement***

As set for above, applicants have elected the invention of Group I, claims 1, 2, 10 and 15, drawn to the polypeptide, SEQ ID NO. 7


***Claim Amendments***

Claims 2-9 and 11-14 have been cancelled, and claim 15 has been amended, so as to conform the claims to the above election, without prejudice to applicants' right to prosecute the non-elected subject matter in one or more divisional applications. Elected claim 10 has been amended to convert it into a method format consistent with U.S. practice.

All claims are believed to be in proper form and directed toward the elected invention. An early and favorable actions on the merits is therefore respectfully requested.

**EXCEPT** for issue fees payable under 37 C.F.R. § 1.18, the Director is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully Submitted,  
**Morgan Lewis & Bockius LLP**



Date: August 1, 2003  
Morgan Lewis & Bockius LLP  
Customer No. **09629**  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
Tel. No.: 202-739-3000  
DJB:mk

By: \_\_\_\_\_

Donald J. Bird  
Registration No. 25,323  
Tel. No.: (202) 739-5320  
Fax No.: (202) 739-3001